GeneTex

  • Country / Location Selection

United States (US)

Cancer Tissue Gallery- GTX04414

SATB2 antibody [MSVA-702R] HistoMAXTM

 

Go to Normal Tissue Gallery Go back to product page Go to HistoMAX page

 

Bone – Osteosarcoma showing a moderate to strong SATB2 positivity of tumor cells.
Bone – Osteosarcoma with strong SATB2 immunostaining of all tumor cells.
Breast – SATB2 negative invasive breast cancer of no special type (NST).
Breast – SATB2 negative invasive lobular breast cancer.
Colon – Colorectal adenocarcinoma exhibiting only a weak SATB2 immunostaining of tumor cells.
Colon – Colorectal adenocarcinoma showing strong SATB2 immunostaining of all tumor cells.
Colon – Colorectal adenocarcinoma with strong SATB2 positivity of tumor cells.
Colon – Colorectal adenoma with intense SATB2 immunostaining of tumor cells.
Colon – Neuroendocrine tumor showing strong SATB2 positivity of tumor cells.
Esophagus – Adenocarcinoma showing a moderate to strong SATB2 staining of tumor cells.
Esophagus – Adenocarcinoma with a weak to moderate SATB2 positivity of tumor cells.
Esophagus – Squamous cell carcinoma depicting a strong SATB2 positivity of the majority of tumor cells.
Kidney – Oncocytoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Kidney – Papillary renal cell carcinoma showing moderate SATB2 immunostaining of tumor cells.
Kidney – Papillary renal cell carcinoma showing weak SATB2 immunostaining of tumor cells.
Kidney – SATB2 negative clear cell renal cell carcinoma.
Kidney – SATB2 negative papillary renal cell carcinoma.
Liver – SATB2 negative cholangiocellular carcinoma.
Lung – SATB2 negative adenocarcinoma.
Lymph node – SATB2 negative diffuse large B-cell lymphoma.
Ovary – SATB2 negative clear cell carcinoma.
Ovary – SATB2 negative serous high-grade carcinoma.
Pancreas – Neuroendocrine tumor showing a faint SATB2 immunostaining of tumor cells.
Pancreas – SATB2 negative ductal adenocarcinoma.
Prostate – SATB2 negative adenocarcinoma (Gleason 3+3=6).
Salivary gland – SATB2 negative pleomorphic adenoma.
Skin – Merkel cell carcinoma showing a moderate to strong SATB2 immunostaining of all tumor cells.
Soft tissue – Leiomyosarcoma showing a faint SATB2 immunostaining of most tumor cells.
Stomach – Gastric adenocarcinoma (diffuse type) showing a weak to moderate SATB2 immunostaining of tumor cells.
Stomach – Gastric adenocarcinoma exhibiting a weak to moderate SATB2 positivity of tumor cells.
Stomach – SATB2 negative gastrointestinal stromal tumor (GIST).
Testis – SATB2 negative seminoma.
Thyroid – SATB2 negative medullary cancer.
Urinary bladder – Muscle-invasive urothelial carcinoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Urinary bladder – Small cell carcinoma with a moderate intensity SATB2 immunostaining of the majority of tumor cells.
Urinary bladder – SATB2 negative muscle-invasive urothelial carcinoma.
Uterus – Endometroid endometrium carcinoma with weak to moderate SATB2 immunostaining of the majority of tumor cells.
Uterus, cervix – SATB2 negative squamous cell carcinoma.
   

| TOP |